ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0310

I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Abstract Number: 0311

Investigation of Sarcoidosis-associated Neuropathy: Challenges with Diagnosis of Small Fiber Neuropathy
Abstract Number: 0312

The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy
Abstract Number: 0313

Cardiac Sarcoidosis Is Associated with a High Mortality: Retrospective Analysis of a Cohort at Mayo Clinic Florida
Abstract Number: 0314

Microvascular Differences Between Acute and Chronic Cutaneous Graft versus Host Disease
Abstract Number: 0315

Microvascular Abnormalities Are Present in Autonomic Dysfunction: Results of a Prospective Study
Abstract Number: 0316

Development and Evaluation of the Adult-onset Still’s Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment
Abstract Number: 0317

Progressive Fibrosing Intersticial Lung Disease of Autoimmune Origin and Antifibrotic Medication: NEREA Registry
Abstract Number: 0318

The Relevance of a Positive ANA in New Patient Referrals to Rheumatology
Abstract Number: 0319

Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Abstract Number: 0320

Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis
Abstract Number: 0321

Diffusion Weighted Imaging in Muscle MRI Can Detect Quantitative Improvements in Muscle Edema: A Post-hoc Analyses of the Study of Tofacitinib in Refractory Dermatomyositis
Abstract Number: 0322

Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging
Abstract Number: 0323

Pain Prevalence and Factors Associated with Pain Levels in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 0324

Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].